Document Detail


Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development.
MedLine Citation:
PMID:  22226479     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Magnetic resonance imaging (MRI) can be made sensitive to diffusion of water molecules in biological tissues: this phenomenon can be quantitated to provide a biomarker, the apparent diffusion coefficient (ADC). Over the past decade, evidence has accumulated from numerous clinical and animal studies that ADC is abnormal in tumours; that elevated ADC reflects an elevated non-cellular fraction; and that acute increases in ADC following therapy can indicate that tumour cells have been killed. However there remain substantial challenges in ensuring robust and valid ADC measurements, particularly in multicentre studies in common sites of metastasis such as lung and liver. Moreover, there is uncertainty about how best to select the timing of observation post-therapy to avoid false-negatives, and how to minimise the confounding factors which could decouple drug-induced ADC increase from drug-induced cell kill. In this review we summarise the physical basis of the biomarker, the evidence that it reflects non-viable fraction, particularly in extracranial tumours, and suggest a roadmap for validation and qualification.
Authors:
Ralph Sinkus; Bernard E Van Beers; Valérie Vilgrain; Nandita Desouza; John C Waterton
Related Documents :
21762029 - Recurrent pseudo-torch appearences of the brain presenting as "dandy-walker" malformation.
11819069 - The ct features of abdominal tuberculosis in children.
21808639 - Molecular imaging in tumor angiogenesis and relevant drug research.
21686679 - Contribution of the 2-[18f]-fluoro-2-deoxy-d-glucose positron emission tomography/compu...
16861559 - Mr enteroclysis of inflammatory small-bowel diseases.
20567529 - Diagnostic evaluation and management of obscure gastrointestinal bleeding: a changing p...
8694529 - Lipid metabolite peaks in pattern recognition analysis of tumour in vivo mr spectra.
18087519 - Holography: an interpretation from the phase-space point of view.
8939219 - Breath-hold single-dose gadolinium-enhanced three-dimensional mr aortography: usefulnes...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-5
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  -     ISSN:  1879-0852     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Affiliation:
Centre de Recherche Biomédicale Bichat Beaujon (CRB3), INSERM U773, Beaujon Hospital, Clichy, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Qualification of imaging biomarkers for oncology drug development.
Next Document:  Imaging apoptosis with positron emission tomography: 'Bench to bedside' development of the caspase-3...